Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | EPRS1 | P07814 | 3/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544183 | 0.84 | PTPN1 (0.47) | PTPN1MCL1ALDH1A1 | |
| SCHEMBL3173623 | 0.83 | SMN1; SMN2 (0.46) | AKR1C3MCL1KDM4EALDH1A1 | |
| SCHEMBL3175389 | 0.83 | NPC1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL3180927 | 0.83 | BCL2L1 (0.44) | TRPV1KDM4EALDH1A1 | |
| SCHEMBL17468485 | 0.81 | MAPT (0.51) | RXFP1PPARATRPV1KDM4EALDH1A1 | |
| SCHEMBL25778740 | 0.81 | IP6K1 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL3546598 | 0.79 | ALDH1A1 (0.56) | RXFP1KDM4EALDH1A1 | |
| SCHEMBL3541658 | 0.79 | NPC1 (0.48) | TRPV1KDM4EALDH1A1 | |
| SCHEMBL27830581 | 0.79 | HRH3 (0.39) | HDAC6KDM4EALDH1A1 | |
| SCHEMBL25778915 | 0.79 | SLC22A12 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| EP-2438048-B1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8273780-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| CN-102459204-A | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS INC | 2012-05-16 | — | — | CN | disclosed |
| EP-2438048-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058300-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141761-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-2051977-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 | Amgen Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | PTPN1 1597/4885RXFP1 1314/4885PPARA 1521/4885 |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | PTPN1 3314/4885RXFP1 3073/4885PPARA 3733/4885 |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | PTPN1 1459/4885RXFP1 235/4885PPARA 137/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | PTPN1 3176/4885RXFP1 2294/4885PPARA 3456/4885 |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | PTPN1 898/4885RXFP1 295/4885PPARA 125/4885 |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | PTPN1 898/4885RXFP1 295/4885PPARA 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.